Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
Apellis Pharmaceuticals Inc (NASDAQ: APLS) closed the day trading at $21.33 down -8.06% from the previous closing price of $23.2. In other words, the price has decreased by -$8.06 from its previous closing price. On the day, 4.02 million shares were traded. APLS stock price reached its highest trading level at $23.0933 during the session, while it also had its lowest trading level at $21.125.
Ratios:
For a better understanding of APLS, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.62 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 34.32. For the most recent quarter (mrq), Quick Ratio is recorded 3.10 and its Current Ratio is at 3.54. In the meantime, Its Debt-to-Equity ratio is 1.18 whereas as Long-Term Debt/Eq ratio is at 0.93.
On October 15, 2025, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $32.
Goldman Downgraded its Neutral to Sell on September 26, 2025, while the target price for the stock was maintained at $18.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 13 ’26 when Nicholson Nur bought 2,618 shares for $22.19 per share.
Chopas James George bought 873 shares of APLS for $19,369 on Jan 13 ’26. On Jan 13 ’26, another insider, Watson David O., who serves as the Officer of the company, bought 5,780 shares for $22.19 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, APLS now has a Market Capitalization of 2698782720 and an Enterprise Value of 2693924864. As of this moment, Apellis’s Price-to-Earnings (P/E) ratio for their current fiscal year is 71.84. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.66 while its Price-to-Book (P/B) ratio in mrq is 6.73. Its current Enterprise Value per Revenue stands at 2.65 whereas that against EBITDA is 32.82.
Stock Price History:
The Beta on a monthly basis for APLS is 0.24, which has changed by -0.2008267 over the last 52 weeks, in comparison to a change of 0.1726681 over the same period for the S&P500. Over the past 52 weeks, APLS has reached a high of $31.17, while it has fallen to a 52-week low of $16.10. The 50-Day Moving Average of the stock is -5.90%, while the 200-Day Moving Average is calculated to be -2.76%.
Shares Statistics:
Over the past 3-months, APLS traded about 2.68M shares per day on average, while over the past 10 days, APLS traded about 2787410 shares per day. A total of 126.50M shares are outstanding, with a floating share count of 103.88M. Insiders hold about 17.90% of the company’s shares, while institutions hold 99.33% stake in the company. Shares short for APLS as of 1767139200 were 16120529 with a Short Ratio of 6.02, compared to 1764288000 on 16097117. Therefore, it implies a Short% of Shares Outstanding of 16120529 and a Short% of Float of 16.770001.
Earnings Estimates
A comprehensive evaluation of Apellis Pharmaceuticals Inc (APLS) is underway, with the input of 11.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.5, with high estimates of -$0.29 and low estimates of -$0.63.
Analysts are recommending an EPS of between $0.48 and $0.04 for the fiscal current year, implying an average EPS of $0.26. EPS for the following year is -$1.32, with 11.0 analysts recommending between -$0.97 and -$1.88.
Revenue Estimates
19 analysts predict $199.39M in revenue. The current quarter. It ranges from a high estimate of $232.4M to a low estimate of $184.82M. As of. The current estimate, Apellis Pharmaceuticals Inc’s year-ago sales were $212.53MFor the next quarter, 19 analysts are estimating revenue of $189.55M. There is a high estimate of $208.5M for the next quarter, whereas the lowest estimate is $170M.
A total of 20 analysts have provided revenue estimates for APLS’s current fiscal year. The highest revenue estimate was $1.05B, while the lowest revenue estimate was $988.69M, resulting in an average revenue estimate of $1B. In the same quarter a year ago, actual revenue was $781.37MBased on 20 analysts’ estimates, the company’s revenue will be $861.28M in the next fiscal year. The high estimate is $955M and the low estimate is $787.62M.
